The in vitro anti-herpes simplex virus type-1 and type-2 activity of long dan xie gan tan, a prescription of traditional Chinese medicine

Chemotherapy

Volumn 54, Issue 2, 2008, Pages 77-83

  Cheng, Hua Yew ^a   Huang, Hsin Hsin ^a,b   Yang, Chien Min ^a   Lin, Liang Tzung ^c   Lin, Chun Ching ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Anti herpes simplex virus activity; Chinese prescription; Long Dan Xie Gan Tan; Traditional Chinese medicine; Virus inactivation

Indexed keywords

ACICLOVIR; CHINESE DRUG; LONG DAN XIE GAN TAN; UNCLASSIFIED DRUG; WATER;

ALISMA; ANGELICA SINENSIS; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BUPLEURUM; CHINESE MEDICINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; GARDENIA; GENTIAN; GLYCYRRHIZA URALENSIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; IC 50; IN VITRO STUDY; NONHUMAN; PLANTAGO; PRIORITY JOURNAL; REHMANNIA; SCUTELLARIA BAICALENSIS; TEMPERATURE DEPENDENCE; VERO CELL; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS INFECTIVITY;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; MEDICINE, CHINESE TRADITIONAL; PHYTOTHERAPY; VERO CELLS;

EID: 41349108546     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000119705     Document Type: Article

References (36)

1. De Clercq E: Molecular targets for antiviral agents. J Pharmacol Exp Ther 2001;297:1-10.
2. Naesens L, De Clercq E: Recent developments in herpesvirus therapy. Herpes 2001;8:12-16.
3. Malvy D, Treilhaud M, Bouee S, Crochard A, Vallee D, El Hasnaoui A, Aymard M; RESSAC Study Group: A retrospective, case-control study of acyclovir resistance in herpes simplex virus. Clin Infect Dis 2005;41:320-326.
4. Christophers J, Clayton J, Craske J, Ward R, Collins P, Trowbridge M, Darby G: Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 1998;42:868-872.
5. Nugier F, Colin JN, Aymard M, Langlois M: Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol 1992;36:1-12.
6. Chen Y, Scieux C, Garrait V, Socie G, Rocha V, Molina JM, Thouvenot D, Morfin F, Hocqueloux L, Garderet L, Esperou H, Selimi F, Devergie A, Leleu G, Aymard M, Morinet F, Gluckman E, Ribaud P: Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000;31:927-935.
7. Danve-Szatanek C, Aymard M, Thouvenot D, Morfin F, Agius G, Bertin I, Billaudel S, Chanzy B, Coste-Burel M, Finkielsztejn L, Fleury H, Hadou T, Henquell C, Lafeuille H, Lafon ME, Le Faou A, Legrand MC, Maille L, Mengelle C, Morand P, Morinet F, Nicand E, Omar S, Picard B, Pozzetto B, Puel J, Raoult D, Scieux C, Segondy M, Seigneurin JM, Teyssou R, Zandotti C: Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004;42:242-249.
8. Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HH Jr: Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Med 1990;112:416-422.
9. Harden EA, Rybak RJ, Hartline C, Gnann JW, Hodges-Savola CA, Wetherall NT, Kern ER; Task Force on Herpes Simplex Virus Resistance: Cross-susceptibility patterns and neuro-virulence of aciclovir-resistant herpes simplex virus isolates collected in a national surveillance study. Antiviral Res 2000;46:A78.
10. Reyes M, Subedar N, Graber JM, Wetherall N, Reeves WC; Task Force on Herpesvirus Resistance: Acyclovir-resistant herpes simplex virus: results from a national surveillance system. Antiviral Res 1998;37:A44.
11. Cheng HY, Lin CC: The antiherpes simplex virus activity of extracts and compounds of natural products. J Trad Med 2005;22(suppl 1):129-132.
12. Kurokawa M, Nagasaka K, Hirabayashi T, Uyama SI, Sato H, Kageyama T, Kadota S, Ohyama H, Hozumi T, Namba T, Shiraki K: Efficacy of traditional herbal medicines in combination with acyclovir against herpes simplex virus type 1 infection in vitro and in vivo. Antiviral Res 1995;27:19-37.
13. Lipipun V, Kurokawa M, Suttisri R, Taweechotipatr P, Pramyothin P, Hattori M, Shiraki K: Efficacy of Thai medicinal plant extracts against herpes simplex virus type 1 infection in vitro and in vivo. Antiviral Res 2003;60:175-180.
14. Li Y, Ooi LSM, Wang H, But PPH, Ooi VEC: Antiviral activities of medicinal herbs traditionally used in southern mainland China. Phytotherapy Res 2004;18:718-722.
15. Chen J, Jiang TL, Wang HL, Liu QY, Shen YJ, Sun XH, Yu QH, Li LD, Wang YM, Wang JH, Wang MZ: The Pharmacology and Application of Famous Chinese Prescription. Taipei, Southern Materials Center Publishing Inc, 1993, pp 423-425.
16. State Pharmacopoeia Commission of the People's Republic of China: Pharmacopoeia of the People's Republic of China. Beijing, Chemical Industry Press, 2000, pp 383-384.
17. Xie M, Zhao H, He YS, X CH, Fan YR, Wang QS, Wang X, Wang L, Wen LX, Fang J, Bai JF: Modern Study of the Medical Formulae in Traditional Chinese Medicine. Beijing, Xue Yuan Press, 1997, vol 2, pp 1360-1365.
18. Cheng HY, Lin TC, Yang CM, Wang KC, Lin CC: Mechanism of action of the suppressing of herpes simplex virus type 2 replication by pterocarnin A. Microbes Infect 2004;6:738-744.
19. Burleson FG, Chambers TM, Wiedbrauk DL: Plaque assay; in Burleson FG, Chambers TM, Wiedbrauk DL (eds): Virology. A Laboratory Manual. San Diego, Academic Press Inc, 1992, pp 74-84.
20. Cheng HY, Lin TC, Yang CM, Shieh DE, Lin CC: In vitro anti-HSV-2 activity and mechanism action of proanthocyanidins A-1 from Vaccinium vitis-idaea. J Sci Food Agric 2005;85:10-15.
21. Cheng HY, Lin TC, Yang CM, Shieh DE, Lin CC: e nt -Epiafzelechin-(4α → 8)-epiafzelechin extracted from Cassia javanica inhibits herpes simplex virus type 2 replication. J Med Microbiol 2006;55:201-206.
22. Talarico LB, Castilla V, Ramirez JA, Galagovsky LR, Waschsman MB: Synergistic in vitro interactions between (22S, 23S)-3β-bromo-5α,22, 23 trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1. Chemotherapy 2006;52:38-42.
23. Yang CM, Cheng HY, Lin TC, Chiang LC, Lin CC: Acetone, ethanol and methanol extracts of Phyllanthus urinaria inhibit HSV-2 infection in vitro. Antiviral Res 2005;67:24-30.
24. Chen CY, Ballard RC, Beck-Sague CM, Dangor Y, Radebe F, Schmid S, Weiss JB, Tshabalala V, Fehler G, Htun Y, Morse SA: Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis 2000;27:21-29.
25. Celum CL, Levine R, Weaver M, Wald A: Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ 2004;82:447-453.
26. Kurokawa M, Ochiai H, Nagasaka K, Neki M, Xu H, Kadota S, Sutardjo S, Matsumoto T, Namba T, Shiraki K: Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their efficacies for HSV-1 infection in mice. Antiviral Res 1993;22:175-188.
27. Ruffa MJ, Perusina M, Alfonso V, Wagner ML, Suriano M, Vicente C, Campos R, Cavallaro L: Antiviral activity of Petiveria alliacea against bovine viral diarrhea virus. Chemotherapy 2002;48:144-147.
28. Newman DJ, Cragg GM, Snader KM: Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-1037.
29. Roizman B, Pellet PE: The family Herpesviridae: a brief introduction; in Knipe DM, Howley PM, Griffin DE, Martin MA, Lamb RA, Roizman B, Straus SE (eds): Fields' Virology, ed 4. Philadelphia, Lippincott Williams & Wilkins, 2001, vol 2, pp 2381-2397.
30. De Clercq E: Antivirals and antiviral strategies. Nat Rev Microbiol 2004;2:704-720.
31. Shen LL, Wu HS, Wang XY: The efficacy of long-dan-xie-gan-tang in the treatment of herpes zoster: a clinical trial and animal experimental data. J Tongji Med Univ 1986;6:109-111.
32. Schacker T: The role of HSV in the transmission and progression of HIV. Herpes 2001;8:46-49.
33. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L: Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002;186:1718-1725.
34. Wald A, Link K: Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002;185:45-52.
35. Celum CL: The interaction between herpes simplex virus and human immunodeficiency virus. Herpes 2004;11(suppl 1):36A-45A.
36. Celum CL, Robinson NJ, Cohen MS: Potential impact of antiviral therapy for HSV-2 and HIV on transmission and acquisition of HIV infection. J Infect Dis 2005;191(suppl 1):S107-S114.